Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
BIIB076 NI-105,
6C5 huIgG1/l
Alzheimer's Disease (Phase 1) Biogen, Eisai Co., Ltd., Neurimmune Tau Immunotherapy (passive)
Bepranemab UCB0107 ,
UCB 0107 ,
Antibody D
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) Hoffmann-La Roche, UCB S.A. Tau Immunotherapy (passive)
Gosuranemab BIIB092,
BMS-986168, IPN007
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Phase 2) Biogen, Bristol-Myers Squibb Tau Immunotherapy (passive)
JNJ-63733657 Mild AD (Phase 1) Janssen Tau Immunotherapy (passive)
Lu AF87908 Alzheimer's Disease (Phase 1) H. Lundbeck Tau Immunotherapy (passive)
PNT001 Alzheimer's Disease (Phase 1), Traumatic Brain Injury (Phase 1) Pinteon Therapeutics Tau Immunotherapy (passive)
RG7345 RO6926496 Alzheimer's Disease (Discontinued) Tau Immunotherapy (passive)
Semorinemab RO7105705 ,
Alzheimer's Disease (Phase 2) AC Immune SA, Genentech, Hoffmann-La Roche Tau Immunotherapy (passive)
Tilavonemab ABBV-8E12,
C2N 8E12,
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Phase 2) AbbVie, C2N Diagnostics, LLC Tau Immunotherapy (passive)
Zagotenemab LY3303560 Alzheimer's Disease (Phase 2) Eli Lilly & Co. Tau, Unknown Immunotherapy (passive)